National Jewish Health’s Post

Is andexanet alfa associated with lower in-hospital mortality for patients with factor Xa inhibitor–related major bleeding? Listen in as Dr. Paul Dobesh analyzes results from a study comparing the in-hospital mortality for patients using andexanet alfa versus those taking a 4-factor prothrombin complex concentrate. He examines the statistically significant reduction in in-hospital mortality for patients with intracranial or GI bleeds utilizing andexanet alfa and discusses the importance of early intervention for these patients, especially those with comorbidities. Tune in to discover data on the role of andexanet alfa in treatment for patients with GI or intracranial bleeding and assess the impact of this important study on real-world clinical practice. Lower in-hospital mortality and optimize care for major bleeds: https://bit.ly/3u5EpxK

Follow Clinical Club Facebook: https://lnkd.in/dKiHNVii Twitter: https://lnkd.in/dN4RAA3P Different Concentrations of Albumin Versus Crystalloid in Patients with Sepsis and Septic Shock: A Meta-Analysis of Randomized Clinical Trials In A Meta-Analysis of Randomized Clinical Trials Albumin treatment, particularly 20% albumin, significantly reduced the 90-day mortality in septic shock patients. Both 4% to 5% and 20% of albumin may work better than crystalloid in improving the survival rate of patients with sepsis, but more relative RCTs are required for validation. Source: https://lnkd.in/dtrMSH3y #clinicalclub

In order to better understand the relationship between frailty and non-acute myocardial infarction with cardiogenic shock, DPHS’ Theresa Coles and Hayden Bosworth joined other experts to analyze the National Inpatient Sample, identify non-AMI-CS hospitalizations, and determine how prevalent frailty is among these patients. Read their results here: https://lnkd.in/eVHk-w6K #populationhealth #publichealth #frailty #AMICS

Vanderbilt researchers recently presented new data on the use of guanfacine in 47 hyperadrenergic #POTS patients. They note that 72% of patients responded well to the medication. Responders experienced improvement in orthostatic symptoms, fatigue and a reduction in the number of “hyperadrenergic episodes.” Of the 13 non-responders, 46% reported a worsening of POTS symptoms while taking guanfacine. Factors that predicted a positive respond included an increase in systolic BP upon standing and distinct blood pressure responses during the Valsalva maneuver (a test performed during autonomic testing). The Vanderbilt researchers suggest a formal clinical trial of guanfacine should be conducted in hyperadrenergic POTS patients. This research was presented as a conference abstract, but the journal charges a fee to read the abstract, which is why we are providing a free summary of the key points. Citation: Clin Auton Res (2023)33: Poster 143.

We're thrilled to announce the publication of our groundbreaking research in The American Journal of Managed Care (AJMC)! Our study introduces "CKD 3-Plus," a game-changing category in chronic kidney disease (CKD) management. This research highlights the importance of early nephrology intervention for individuals with stage 3 CKD and specific comorbidities, showing they benefit from proactive care typically reserved for more advanced stages. These insights call for expanding access to value-based models to even more people living with kidney disease, allowing them to experience the comprehensive care that Evergreen and its physician partners provide. Key findings reveal: High-Risk Identification: About 35% of CKD stage 3 patients, termed CKD 3-Plus, show progression and healthcare costs similar to later stages. Cost and Utilization: CKD 3-Plus patients incur higher medical costs and have more frequent hospital admissions, presenting opportunities to improve care and reduce expenses. Improved Outcomes: Early intervention can significantly improve patient outcomes, including better dialysis preparation and increased transplant rates. Our collaboration with AJMC has been invaluable in bringing this critical research to the forefront. This study is a testament to our commitment to enhancing patient care through value-based models, ultimately improving lives and reducing healthcare costs. Join us in celebrating this milestone as we continue to innovate and lead in kidney care. Together, we're making a difference! 🌟 #KidneyCare #HealthcareInnovation #ValueBasedCare #EvergreenNephrology #AJMC https://lnkd.in/eHdigGr8 (Article live on AJMC’s site Monday morning)

🌟𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐍𝐞𝐰𝐬: 𝐔𝐒𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐑𝐞𝐳𝐝𝐢𝐟𝐟𝐫𝐚, 𝐚 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐚𝐫𝐲 𝐌𝐀𝐒𝐇 𝐃𝐫𝐮𝐠 - 𝐀 𝐆𝐚𝐦𝐞-𝐂𝐡𝐚𝐧𝐠𝐞𝐫 𝐢𝐧 𝐋𝐢𝐯𝐞𝐫 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭!! 🌟 Key Points: ▪ Rezdiffra is the 1st USFDA approved therapy for MASH, addressing a long-standing medical need. ▪ Priced at USD 47,400, it is positioned to be cost-effective for patients. ▪ No liver biopsy required for eligibility, improving accessibility and patient experience. ▪ Estimated to impact about 5% of adults in the US, this approval paves the way for future developments in the field. Share your thoughts on this groundbreaking approval and its implications for healthcare. How do you see this impacting the future of liver disease treatment? Comment below! Learn more about our work on similar indications here: https://lnkd.in/ggvea2PU

Please join an interprofessional faculty panel of experts, including Jonathan Silverberg, MD, and Lindsay C. Strowd, MD as they share their real-world perspectives on the diagnosis and treatment of patients with prurigo nodularis to reduce patient burden of disease and improve health outcomes. Highlighting pathophysiologic mechanisms, the faculty discuss the evolving pharmacologic treatment of patients with prurigo nodularis that now includes dupilumab; they also review safety and efficacy data for medications in late-phase clinical investigation. Case studies are discussed to facilitate integration of key concepts into clinical practice. https://lnkd.in/gjz3_-2e

🚨Epinephrine vs. Norepinephrine in Post-Resuscitation Shock 🚨 A groundbreaking multicenter study (2011-2018) involving 766 patients has cast new light on a pivotal choice in post-resuscitation care. When it comes to treating post-resuscitation shock following out-of-hospital cardiac arrests, the choice of vasopressor can be a matter of life and death. 💡 Key Findings: • Patients treated with epinephrine faced significantly higher all-cause and cardiovascular-specific hospital mortality. • Unfavorable neurological outcomes were also more prevalent in the epinephrine group. The study suggests a potential shift towards norepinephrine as a safer option until more data is available. As healthcare professionals, it’s essential to stay informed about such critical findings to make the best decisions for our patients. Let’s discuss: How might these findings influence your approach to post-resuscitation care? #CriticalCare #Paramedics #CardiacArrest #Epinephrine #Norepinephrine #PatientCare #HealthcareResearch

A new Italian study indicates that the implementation of structured and integrated models of care (such as Fracture Liaison Services) increased the BMD testing rate and the initiation and adherence to anti-osteoporotic medication, reduced the risk of subsequent fracture and mortality, and improved HRQoL and the physical function of patients experiencing a fragility fracture. #CaptureTheFracture https://bit.ly/3r1XHmA

The underestimated importance of Lean Mass in Clinical Outcomes In healthcare the is often a focus on symptoms, disease progression, and treatment efficacy. However, one often-overlooked factor plays a critical role in patient outcomes: Lean Mass. Research has shown that a drop in lean mass or appendicular lean mass is strongly associated with worse clinical outcomes across a spectrum of diseases, including sarcopenia, cardiovascular diseases, diabetes, cancer cachexia, and more. Despite its significance, lean mass is not tracked as closely as it should be in clinical settings. This oversight can lead to missed opportunities for intervention and improvement in patient care. But there's a tool that can be used to help guide clinical assessments - which is where Bodystats Bioimpedance Spectroscopy (BIS) analyser is perfectly positioned. BIS offers a comprehensive understanding of body composition, going beyond simple metrics like weight and BMI. It provides valuable insights into the proportion of lean mass, fat mass, and water compartments in the body. By incorporating BIS into patient assessments, healthcare professionals can unlock a deeper understanding of a patient's health status, tailor treatments more effectively, and ultimately, drive improved outcomes. By building an accurate body composition patient profile through technologies like BIS, we can enhance patient care, support better recovery trajectories, and contribute to the overall well-being of our patients. #patientoutcomes #bodycomposition